1. Home
  2. NXJ vs AUTL Comparison

NXJ vs AUTL Comparison

Compare NXJ & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuveen New Jersey Qualified Municipal Fund

NXJ

Nuveen New Jersey Qualified Municipal Fund

HOLD

Current Price

$12.41

Market Cap

503.5M

Sector

Finance

ML Signal

HOLD

Logo Autolus Therapeutics plc

AUTL

Autolus Therapeutics plc

HOLD

Current Price

$1.87

Market Cap

407.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NXJ
AUTL
Founded
1999
2014
Country
United States
United Kingdom
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
503.5M
407.2M
IPO Year
N/A
2025

Fundamental Metrics

Financial Performance
Metric
NXJ
AUTL
Price
$12.41
$1.87
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$8.50
AVG Volume (30 Days)
90.1K
1.6M
Earning Date
01-01-0001
05-14-2026
Dividend Yield
3.27%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$10,120,000.00
Revenue This Year
N/A
$80.32
Revenue Next Year
N/A
$53.96
P/E Ratio
N/A
N/A
Revenue Growth
N/A
496.00
52 Week Low
$11.06
$1.18
52 Week High
$12.90
$2.70

Technical Indicators

Market Signals
Indicator
NXJ
AUTL
Relative Strength Index (RSI) 55.04 64.77
Support Level $11.94 $1.27
Resistance Level $12.76 $1.98
Average True Range (ATR) 0.09 0.13
MACD 0.01 0.02
Stochastic Oscillator 69.38 86.54

Price Performance

Historical Comparison
NXJ
AUTL

About NXJ Nuveen New Jersey Qualified Municipal Fund

Nuveen New Jersey Quality Municipal Income Fund is a closed-end investment management company. Its objective is to provide current income exempt from regular federal and New Jersey income tax and to enhance portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds that the Fund's investment adviser believes are underrated or undervalued or that represent municipal market sectors that are undervalued. The company invests a majority of its managed assets in securities rated, at the time of investment, investment grade or, if the bonds are unrated, are judged by the manager to be of comparable quality.

About AUTL Autolus Therapeutics plc

Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms.

Share on Social Networks: